17,261 trials
Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma
Primary: Overall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.1 — 38.7 percentage of participants — p=0.0002
Non-segmental Vitiligo
Primary: Mean Change From Baseline in Vitiligo Area Scoring Index Score — -0.472; -0.271; -0.706; -1.145 score on a scale — p=0.7905
Priapism
Primary: Percent Change in Priapic Events From Baseline to 26 Weeks — -61.3 Percent change from baseline — p=0.0676
Atopic Dermatitis · Skin Diseases
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 — -55.1; -52.2; -61.4; -50.4 percent change — p=0.505
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Biphenotypic Acute Leukemia
Primary: Disease Free Survival — 70.6 percentage of participants — p=0.002
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
NSCLC · Metastatic Colorectal Carcinoma · Refractory Melanoma
Primary: Objective Response Rate (ORR) — 40; 37.5; 60; 62.5 percentage of patients — p=1.0000
Edematous Fibrosclerotic Panniculopathy · Cellulite
Primary: Percentage of Participants With at Least 1-Level Lower Score 3 to 5 Days After Initial CCH-aaes Injection, as Assessed by the Investigator Assessment of Bruising…
Alzheimer Disease
Primary: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) — 34; 26 Participants
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Primary: Overall Survival — 28; 15; 53; 7 Participants
Risk Reduction · Mammographic Density Reduction
Primary: Mammograpic Density Change — -9.6; -6.8; -1.0; -6.9 Percentage of change — p=<0.01
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Breast Cancer · Overweight or Obesity
Primary: Number of Patients With 5 Percent Weight Loss (in SLOW-BWL) — 16 Participants
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 — -13.0; -12.4; -10.8; -10.8 Units on a scale — p=0.7636
Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Recurrent Squamous Cell Carcinoma of the Head and Neck · Metastatic Head and Neck Cancer
Primary: Best Overall Response (BOR) Rate — 0.19 proportion of participants